Publications en collaboration avec des chercheurs de Hospital Universitario La Paz (9)

2024

  1. Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607

2023

  1. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

    BMC Infectious Diseases, Vol. 23, Núm. 1

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

    AIDS (London, England), Vol. 36, Núm. 15, pp. 2171-2179

2021

  1. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2015

  1. Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 40.e1-40.e16

  2. Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 33, Núm. 1, pp. 41-47

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

2006

  1. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: A cross-sectional study

    Cardiovascular Diabetology, Vol. 5